12LBA Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSe Program. Issue 3 (September 2015) - Vassal, G.; Moro-sibilot, D.; Le Deley, M.C.; Hoog-labouret, N.; Nowak, F.; Jimenez, M.; Tournigand, C.; Houot, R.; Malka, D.; Aparicio, T.; Escudier, B.; Ray-coquard, I.; et al.